Aprepitant as add-on to standard antiemetic regimen for concurrent chemoradiotherapy induced nausea vomiting in head and neck cancer

Table 3 Secondary efficacy outcomes, n/N (%)

Efficacy parameter	Acute-phase			Delayed-phase
	Group A	Group B	P value	Group A	Group B	P value
Complete protection	42/43 (97.7)	35/43 (81.4)	0.014	33/43 (76.7)	22/43 (51.2)	0.013
Degree of nausea as per CTCAE criteria1
Grade 1	5/43 (11.63)	4/43 (9.30)	0.72	9/43 (20.93)	17/43 (39.53)	0.06
Grade 2	0/43	12/43 (27.90)	0.0001	5/43 (11.63)	11/43 (25.58)	0.09
Degree of vomiting as per CTCAE criteria2
Grade 1	0/43	3/43 (6.8)	0.07	1/43 (2.3)	0/43	0.31
Grade 2	0/43	3/43 (6.8)	0.07	3/43 (6.8)	9/43 (20.9)	0.06

¹Grade 1: Loss of appetite without alteration in eating habits; Grade 2: Oral intake decreased without significant weight loss, dehydration, malnutrition; Grade 3: Inadequate oral caloric or fluid intake; tube feeding; total parenteral nutrition; hospitalization.

²Grade 1: Intervention not indicated; Grade 2: Outpatient IV hydration, medical intervention indicated; Grade 3: Tube feeding, total parenteral nutrition or hospitalization indicated; Grade 4: Life threatening consequences; Grade 5: Death.

Data analysed by Pearson χ² test. CTCAE: Common terminology criteria for adverse events.